- Home
- Semaglutide
Semaglutide
- CAS: 910463-68-2
- Formula: C187H291N45O59
- Molecular mass: 4113.641 g·mol−1
- Storage temperature: -15°c~-25°c
Indications
Semaglutide Pharmaserve is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct of diet and exercise. The approved therapeutic doses are 0.5 mg and 1 mg. Diabetes mellitus type 2 is a long-term metabolic disorder characterized by high blood sugar, insulin resistance and lack of insulin. Its onset is determined by the loss ability of beta cells to respond to an increased plasma glucose. This disease is predominantly caused by lifestyle factors like overweight and obesity. The key feature on type 2 diabetes is the presence of insulin resistance which reduced the capacity of insulin to exert its functions at normal at any given concentration. The secretion of insulin is stimulated by the action of incretins in the gut like glucagon-like peptide 1, which also delays gastric emptying and induces satiety, and glucose-dependent insulinotropic polypeptide.
Pharmacodynamics
In clinical trials, Semaglutide Pharmaserve reduced significantly the glycated hemoglobin (HbA1c) compared to other medications like sitagliptin, exenatide and insulin glargine U100. The HbA1c protein is a standard measure of high glucose as in normal conditions the hemoglobin forms 1-deoxyfructose. In the trials, it was also showed the ability of Semaglutide to reduce the body weight. After 12 weeks of treatment, Semaglutide lowered fasting and postprandial glucose concentrations by increasing insulin production and decreasing glucagon secretion. It also lowered fasting triglycerides and VLDL cholesterol.
Mode of Action
Drugs like Semaglutide Pharmaserve affect the glucose control through several different mechanisms like the increase of insulin secretion, slow of gastric emptying, and reduction of postprandial glucagon and food intake. The glucose homeostasis depends on hormones like insulin and amylin secreted in pancreatic beta cells, glucagon secreted in pancreatic alpha cells and gastrointestinal peptides like glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide. When glucose is administered orally, GLP-1 will stimulate the synthesis of insulin by stimulating pancreatic islets, it will also slow the gastric emptying, inhibit post-meal glucagon release and reduce food intake. GLP-1 has a major role in glucose management and Semaglutide presents an analog structure which allows it to perform all the activities of GLP-1. The innovative section of Semaglutide is the presence of structural modifications (amino acid substitution at position 8) that generate superior stability against dipeptidyl peptidase-4 which is an enzyme that degrades incretins like GLP-1. The structure of Semaglutide (lysine acylation with a spacer and C-18 fatty di-acid at position 26) also permits an increased and specific binding to plasma albumin; as well as a modification (amino acid substitution at position 34) that prevents C-18 fatty di-acid binding in wrong sites. All these characteristics donate Semaglutide with an extended half-life, increasing patient compliance and quality of life.
Toxicity
In preclinical toxicity studies with Semaglutide Pharmaserve, there was observed the presence of mild c-cell hyperplasia, nests and dilated ultimobranchial ducts after three months of exposure with the clinical dose. There was also reports of liver necrosis and centrilobular hypertrophy mainly in man in the same doses. Some ECG abnormalities and multifocal vacuolation and degeneration were observed in high dose studies.
Metabolism
The metabolism of Semaglutide Pharmaserve is slowly but extensively metabolized prior to excretion. This was observed as 83% of the administered dose found in the plasma is composed of the unchanged drug. As a product of the metabolism, six different metabolites were identified in human plasma in which the major metabolite, named P3, accounted for 7.7% of the administered dose, thus indicating a component below the relative exposure limit in the safety assessment. The metabolites were formed following proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain. The known enzymes to be involved in the degradation of Semaglutide are dipeptidyl peptidase (DPP-4) and neural endopeptidase (NEP). DPP-4 inactivates semaglutide truncating the N-terminal sequence and NEP hydrolyze peptide bonds.
Ozempic(Semaglutide Injection)
- 0.25mg
- 0.5mg
- 1mg
- 2mg
Rybelsus(oral Semaglutide)
- 7mg
- 14mg
Wegovy(Semaglutide Injections)
- 0.25mg
- 0.5mg
- 1mg
- 1.7mg
- 2.4mg
Emergency?
24 Hour Ready
Call Us for Emergency
+146002
Book Appointment
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
How it works
Procedure and Process Treatment
Diagnosis and Treatment
Ozempic® (semaglutide) is an injectable prescription medicine used to manage Type 2 diabetes. It comes in doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. Ozempic helps lower blood sugar levels by improving insulin secretion and reducing glucose production in the liver.
Find a Doctor
To find a doctor who can prescribe Ozempic® shot, consult your primary care physician or an endocrinologist specializing in diabetes management. They can assess your condition and determine if Ozempic® is suitable for your treatment plan.
Ozempic® Dosing Guide for A1C Control
The beginning dose is 0.25 mg once a week for the first 4 weeks. At Week 5, your health care provider will increase the dose to 0.5 mg once a week. Your A1C needs may shift as your type 2 diabetes changes.
Semaglutide's Effectiveness in Diabetes
Semaglutide has been shown to reduce HbA1c by 1.5% to 1.8% in type 2 diabetes patients. Studies like SUSTAIN China and SUSTAIN 6 reported an 86.1% HbA1c compliance rate, with very low hypoglycemia rates. Additionally, semaglutide significantly reduces the risk of cardiovascular events, including a 39% reduction in stroke risk.
Pharmaserve’s Technology of Synthesis
Semaglutide API Solid phase reactor is required in the production of Semaglutide API. Pharmaserve adopts a new type of special solid phase reactor for Semaglutide, including reactor shell, air inlet pipe, air outlet pipe, gas distribution component and solid phase catalytic component. In the production process of Semaglutide product itself, the equipment of the invention is suitable for solid phase catalytic reaction, which improves the reaction effect, shortens the reaction time, and is suitable for the production of Semaglutide, making the final product more pure.
When the device of the invention is used to produce Semaglutide Pharmaserve API, the overall reaction time is reduced by 20% ‑ 30%; At the same time, the production cost of the whole process is reduced, making the cost reduced by about 10%, which is suitable for promotion and use, and promoting the further research and development of Semaglutide.
Purification of Pharmaserve Semaglutide API
There are many impurities in the crude product of solid phase synthesis of Semaglutide that affect the purity and yield of the sample. At present, there are many studies on the purification of Semaglutide, and the purity can reach more than 99%. However, the solubility of the finished product obtained by the existing purification methods is not good, and other means are needed to improve the solubility of the finished product in the subsequent research and application process. Pharmaserve uses the latest peptide purification technology. The purity of the finished product reaches 99%, and the single impurity is less than 0.2%. At the same time, the solubility of the finished product is good, and the sample recovery rate can reach 100%. This process is stable and controllable, suitable for industrial production, and it can effectively reduce your scientific research or industrial needs.
FAQ
Frequently Ask Questions
Ozempic® is used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
There are a number of reasons that Ozempic® could be right for you if you have type 2 diabetes and you're struggling to lower your blood sugar and reach your A1C goal.
- Ozempic® is proven to lower A1C.
- Ozempic® lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults also with known heart disease.
Ozempic® may help you lose some weight.
Ozempic® is not a weight‑loss drug.
Ozempic® injection 0.25mg, 0.5 mg, 1 mg, 2 mg is an injectable prescription medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). It also lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes and known heart disease.
Ozempic® is approved by the FDA for adults with type 2 diabetes to lower blood sugar, along with diet and exercise, and reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease. People respond to medicines differently. That's why it is important to talk to your health care professional about any questions you may have about your treatment plan.Ozempic® is not FDA approved for weight loss or chronic weight management.
No. We are aware that there are companies claiming to have availability of compounded Ozempic® or semaglutide. We want consumers to know that Novo Nordisk does not sell prescription-only medicine Ozempic®, or its active ingredient, semaglutide, for the purposes of compounding with other products.
We have not conducted studies to evaluate the safety and efficacy of Ozempic® when compounded with other ingredients. Novo Nordisk is the only company that has FDA approval to market Ozempic® and we supply it in a branded box that includes a proprietary pen and the FDA-approved prescribing information. Novo Nordisk does not make Ozempic® in a vial that comes with a separate syringe.
No—other Novo Nordisk products exist that contain semaglutide.
Rybelsus(Tablets), for Type 2 Diabetes, tablets 7 mg or 14 mg is a prescription medicine.
Wegovy(Injection), Weight loss, 0.25 mg , 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injectable prescription medicine.
